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Abstract
Background: Musculoskeletal conditions are highly prevalent, and knee OA is most common. Current treatment
modalities have limitations and either fail to solve the underlying pathophysiology or are highly invasive. To
address these limitations, attention has focused on the use of biologics. The efficacy of these devices is attributed
to presence of growth factors (GFs), cytokines (CKs), and extracellular vesicles (EVs). With this in mind, we
formulated a novel cell-free stem cell-derived extract (CCM) from human progenitor endothelial stem cells (hPESCs).
A preliminary study demonstrated the presence of essential components of regenerative medicine, namely GFs,
CKs, and EVs, including exosomes, in CCM. The proposed study aims to evaluate the safety and efficacy of
intraarticular injection of the novel cell-free stem cell-derived extract (CCM) for the treatment of knee OA.
Methods and analysis: This is a non-randomized, open-label, multi-center, prospective study in which the safety
and efficacy of intraarticular CCM in patients suffering from grade II/III knee OA will be evaluated. Up to 20 patients
with grade II/III OA who meet the inclusion and exclusion criteria will be consented and screened to recruit 12
patients to receive treatment. The study will be conducted at up to 2 sites within the USA, and the 12 participants
will be followed for 24 months. The study participants will be monitored for adverse reactions and assessed using
Numeric Pain Rating Scale (NPRS), Patient-Reported Outcomes Measurement Information System (PROMIS) Score,
Knee Injury and Osteoarthritis Outcome Score Jr. (KOOS Jr.), 36-ietm short form survey (SF-36), Single Assessment
Numeric Evaluation (SANE), physical exams, plain radiography, and magnetic resonance imaging (MRI) with
Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score for improvements in pain, function,
satisfaction, and cartilage regeneration.
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Discussion: This prospective study will provide valuable information into the safety and efficacy of intraarticular
administration of cell-free stem cell-derived extract (CCM) in patients suffering with grade II/III knee OA. The
outcomes from this initial study of novel CCM will lay the foundation for a larger randomized, placebo-controlled,
multi-center clinical trial of intraarticular CCM for symptomatic knee OA.
Trial registration: Registered on July 21, 2021. ClinicalTrials.gov NCT04971798
Keywords: Musculoskeletal injuries, Knee osteoarthritis, Regenerative medicine, Stem cells, Progenitor cells, Growth
factors, Cytokines, Extracellular vesicles, Exosomes, Clinical trial
Background
Osteoarthritis (OA) and other orthopedic acute and de-
generative conditions affect millions of people each year,
resulting in marked pain and disability [1–3]. Knee OA
is the most prevalent and is estimated to affect 67 mil-
lion people by the year 2030 [4]. Conservative modalities
are limited, as they do not reverse the underlying path-
ology and may only provide symptomatic relief [3–11].
To address the limitations of traditional conservative
modalities, there has been substantial interest in
biologics for musculoskeletal regenerative medicine
applications [6, 12]. The efficacy of biological products is
attributed to the presence of growth factors (GFs), cyto-
kines (CKs), and extracellular vesicles (EVs) including
exosomes [13–16].
First-generation biologics, specifically whole stem cell
products, are not without limitations, including estab-
lishing a reliable source with a stable phenotype, genetic
instability and chromosomal aberrations, intravenous
administration-related toxicities caused by the physical
trapping of the cells in the lung microvasculature, rejec-
tion by the host, formation of ectopic tissue, and tumori-
genicity [17–20].
When considering how to harness the value of current
biologics into a next generation product that can address
existing limitations, it is important to consider the
current knowledge regarding the mechanism of action of
stem cell products. The recent literature regarding the
beneficial effects of mesenchymal stem cells (MSCs)
postulates that the mechanism of action does not result
from their ability to grow and differentiate. Rather, it is
secondary to their secretion of bioactive molecules such
as GFs, CKs, and exosomes [21–24]. GFs, secreted from
stem cells, induce signal transduction pathways that
initiate cell migration, proliferation, growth, and differ-
entiation [25]. CKs, similarly, can regulate inflammation,
immune response, cellular differentiation, and tissue
remodeling [26]. Exosomes also are secreted by mesen-
chymal stem cells and act as a paracrine mediator to
target cells, providing a regenerative microenvironment
for damaged tissues [23, 27, 28].
As the existing literature establishes that these compo-
nents of stem cells produce definite regenerative responses,
we have accordingly sought to establish whether a
sub-cellular approach to biologics can provide similar
benefits while avoiding the risk profile, including im-
munogenicity, infection, and the potential for tumori-
genicity, associated with whole stem cell products.
Supporting this hypothesis, recent studies have dem-
onstrated that MSCs-derived exosomes can act as a
cell-free therapeutic alternative to whole cell therapy
with great regenerative potential [29–31]. In addition
to the benefits by means of risk elimination, there
may be further therapeutic benefits of a cellular de-
rived therapeutic approach. For example, exosomes,
given their smaller size, have the potential to migrate
to target organs efficiently, without getting trapped in
the lung microvasculature [32, 33]. Additionally, a
higher concentration of “active ingredients” can be
administered directly to the patient, which may in-
duce a greater healing response than possible with
whole stem cell therapies.
To meet these goals of improving the risk profile and
therapeutic benefit of regenerative medicine, we have
formulated a novel cell-free stem cell-derived extract
(CCM) from human progenitor endothelial stem cells
(hPESCs). Our preliminary results demonstrated the
presence of several GFs, anti-inflammatory CKs and EVs
including exosomes in this formulation [34]. Function-
ally, this formulation also significantly enhanced cell
proliferation and induced stem cell migration [34].
The goal of this proposed study is to evaluate the
safety and efficacy of intraarticular injection of this cell-
free stem cell-derived extract formulation for the man-
agement of knee OA. We hypothesize that intraarticular
administration of this cell-free stem cell-derived extract
formulation is safe. We also hypothesize that patients re-
ceiving intraarticular injection of this formulation will
show an improvement in their overall satisfaction,
Numeric Pain Rating Scale (NPRS), Patient-Reported
Outcomes Measurement Information System (PROMIS)
score, and Knee Injury and Osteoarthritis Outcome
Score (KOOS Jr.) over a period of 2 years compared to
baseline. We wish to test the null hypothesis that there
is no difference between baseline and follow-up visits for
the outcome measures considered.
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Methods and analysis
The Standard Protocol Item-Recommendations for
Intervention Trials (SPIRIT) criteria were used to report
this study protocol [35]. The complete SPIRIT checklist
can be found within the supplementary data.
Study design
Up to 20 patients with grade II/III OA who meet the in-
clusion and exclusion criteria will be consented and
screened to allow for approximately 12 patients to re-
ceive treatment for this non-randomized, open-label,
multi-center, prospective study. This study will be con-
ducted at two sites within the USA, and the participants
will be followed for 24 months after the intervention.
Figure 1 summarizes the trial design, and Fig. 2 illus-
trates the enrolment, intervention, and assessment
according to the SPIRIT guidelines.
Inclusion criteria
Patients will be considered for inclusion in the study if
they meet the following criteria:
1. 18 years of age or older
2. BMI of ≤ 35Kg/m2
3. Willing and capable of providing informed written
consent
4. Willing and capable of subjective evaluation and
able to understand written questionnaires
5. Diagnosed with mild to moderate knee OA in only
one knee with a grade II/III on the Kellgren
Lawrence (KL) grading scale
6. Average knee pain intensity of ≥ 6 on the NPRS
7. Willing to not take any knee symptom modifying
drugs through the end of the study
8. Willing and able to comply with study-related
requirements, procedures, and visits
9. If female, sexually active, and of childbearing age,
patients must be willing to use a reliable form of
birth control throughout the duration of the study.
If male, sexually active, and with partners of
childbearing age, patients must be willing to use
contraceptive measures.
Exclusion criteria
In addition to the inclusion criteria, patients must not
meet any of the following exclusion criteria:
1. Taken any pain medications, including NSAIDS,
within 15 days prior to the study injection date.
2. Use of anticoagulants or history of the regular use
of anticoagulants
3. History of addiction to dependency producing
medications or substance abuse, including alcohol
or illicit drugs
4. Mechanical knee symptoms consistent with
extensive intraarticular pathology not amenable to
injection therapy alone, including clinical or
imaging evidence of anterior cruciate ligament,
posterior cruciate ligament, medial collateral
ligament, lateral collateral ligament, or meniscal
pathology
5. Undergone an intraarticular injection of any drug
or device including but not limited to
corticosteroid, platelet rich plasma or
viscosupplementation in the index knee within the
last 3 months
6. History of any type of surgery in the index knee
7. Recent (within 3 months) history of traumatic
injury
8. Planned elective knee surgery during the duration
of the study
9. History of organ or hematologic transplantation
Fig. 1 Summary of trial design
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10. History of rheumatoid arthritis or other
autoimmune disorders
11. History of immunosuppressive medication/
treatment or cancer diagnosis within the last 5 years
12. Current knee infection or history of using
antibiotics for a knee infection within the last 3
months
13. Participation within another clinical study or
received treatment with any investigational product
within 30 days of enrollment
14. Currently pregnant, as determined by urine testing
15. Breastfeeding, or desires pregnancy during the
course of the study
16. Contraindications to plain radiography or MRI
imaging
17. Diagnosis of progressive neurological disease
18. Diagnosis of an active psychological or psychiatric
disorder
19. Pain within other areas and/or medical conditions
that could interfere with pain reporting, study
procedures, and/or confound evaluation of the
study
20. Unresolved major issues of secondary gain (e.g.,
social, financial, or legal)
Study intervention
After the patients have meet all inclusion/exclusion cri-
teria during visit 1 (preliminary/baseline), they will re-
ceive an intraarticular injection of CCM (2ml, General
Therapeutics LLC, Cleveland Heights, OH, USA) formu-
lation via anterolateral approach by the site principal in-
vestigator (PI) utilizing ultrasound guidance per PI’s
standard institutional protocol during visit 2.1 (injection
visit/procedure).
Assessment points
The assessments for the study period will begin at visit 1
(preliminary/baseline), where patients will be screened
for the inclusion/exclusion criteria and asked to sign the
informed consent form. Once enrolled, the demographic
information, medical history, medication history, and vi-
tals will be collected. A baseline physical exam (PE) that
includes knee ligament laxity and active/passive range of
motion evaluation will be performed. Baseline plain radi-
ography (weight bearing anteroposterior, lateral with 30°
of knee flexion, Merchant and Rosenberg views) and
MRI imaging (including T2 imaging and institutional
standard protocol) will be performed for OA grading
using the KL scale and Magnetic Resonance Observation
of Cartilage repair Tissue (MOCART) score, respect-
ively. Baseline case report forms (CRFs) including NPRS,
KOOS Jr., PROMIS, Neuro-QoL Short Form v1.0, Lower
extremity function-Mobility, PROMIS Short Form V2.0
- Physical Function 10a and 10b, and patient satisfac-
tion/survey (SF-36 and Single assessment Numeric
Evaluation (SANE)) will be collected. Additionally, a
comprehensive metabolic profile (CMP), creatinine (Cr),
erythrocyte sedimentation rate (ESR), T, B, and NK cell
Fig. 2 Standard protocol items: recommendations for interventional trials (SPIRIT) flowchart
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lymphocytes subsets, and serum IgG, IgA, IgM, and IgE
levels will be collected. The vitals will be recorded
followed by administration of injection by the site PI on
visit 2.1. During visit 2.2 (immediately after injection
follow-up + 15min after injection), the vitals and NPRS
will be recorded. Visits 3 (24 h follow-up ± 2 h) and 4
(48 h follow-up ±2 h) will be completed via phone inter-
view, and NPRS will be collected. On visit 5 (1 week
follow-up ±1 day), a PE will be performed and specific
CRFs (NPRS, KOOS Jr., PROMIS, 5 point Likert scale
and SANE) as well as a comprehensive metabolic profile
(CMP), creatinine (Cr), erythrocyte sedimentation rate
(ESR), T, B, and NK cell lymphocytes subsets, and serum
IgG, IgA, IgM, and IgE levels will be collected. The exact
same process will take place through visits 6 (6 week
follow-up ± 3 days), 7 (3 month follow-up ± 7 days), and
8 (6 month follow-up ± 14 days) with a plain radiograph
at each visit. SF-36 will also be collected at visits 7 and
8. At visit 9 (12 month follow-up ± 21 days), the partici-
pants will undergo the aforementioned processes with
an MRI for MOCART grading. At visit 10 (18 month
follow-up ± 28 days), the participants will undergo a PE,
plain radiography, and CRFs (NPRS, KOOS Jr., PROMIS,
5 point Likert Scale, SANE and SF-36). At visit 11 (24
month follow-up ± 28 days), the participants will
undergo the aforesaid processes with an MRI for
MOCART grading. An empirical grading form evaluat-
ing six distinct articular elements namely, cartilage,
osteophytes, subchondral sclerosis, bone marrow lesions,
joint effusion, and synovitis, involved in the pathoanat-
omy of knee osteoarthritis using MRI will also be evalu-
ated at baseline and at 12- and 24-month follow-up
visits [36]. Participants may report any adverse events or
changes in medications at any point during the study.




1. To determine the safety of intraarticular
administered CCM, including monitoring for
adverse injection reactions including immunogenic
or allergic responses or infection.
Secondary endpoints
1. To assess the changes if any in patient-reported
outcome measures, NPRS, PROMIS, and KOOS Jr.,
from baseline to different follow-up time points.
2. To assess cartilage formation via MOCART at 2
years time point and compare it from baseline.
3. To assess patient satisfaction.
Sample size and statistical analysis
Descriptive statistics will be computed for all study vari-
ables. Continuous variables will be described with mea-
sures of central tendency (mean, median) and dispersion
(range, standard deviation). Categorical variables will be
summarized as frequencies and percentages. Compari-
sons between categorical variables will be compared with
the chi-Square test; continuous variables will be com-
pared with Student’s t test or nonparametric equivalents.
Paired continuous data will be assessed with a paired t
test or Wilcoxon signed rank test, depending on distri-
bution. Paired categorical data will be assessed with the
McNemar’s test. For the longitudinal data, a mixed
model repeated measures analysis will be used to exam-
ine the between subject factors and the within subject
factor of time (baseline, visit 1, visit 2, etc.), as well as
their interaction, on the outcome variables of interest.
Post hoc tests with corrections for multiple comparisons
will be run to determine where significance lies. P values
< 0.05 will be considered statically significant.
Data collection and handling
The PI will be responsible for the maintenance of source
documents and records for a period of 7 years. Data will
be transcribed on paper study CRFs, and the original
data will be secured by the PI and made available to the
sponsor and study monitors. All CRFs will be subject to
initial inspection for omitted data, data inconsistencies,
illegible data, and deviations by study monitors. All hard
copies of CRFs and media will be stored in a secure loca-
tion for 7 years.
The PI will be responsible for submitting data and re-
ports as follows:
a. AEs: In an ongoing basis. This will be reported in
the proper section of the CRF.
b. SAEs: Report within 24 h of knowledge of event to
sponsor and report to IRB within 5 days as per
their regulations.
c. Deviations, exceptions, violations of protocol:
Report to sponsor within 5 days and report to IRB
per their regulations.
d. Protocol progress report: Provide a copy to sponsor
and IRB as per regulations.
e. Study closure report: Provide a copy to sponsor and
IRB as per regulations.
Quality control and assurance
All documents related to the study will be produced and
maintained to ensure control and protection of patient’s
privacy. The sponsor, study monitors, and representa-
tives of regulatory authorities are permitted to access all
study documents (e.g., protocol, CRFs, medical records/
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files) as needed. All attempts will be made to preserve
patients’ privacy and confidentiality.
Discussion
OA is one of the most common musculoskeletal condi-
tions in the USA, affecting several joints and leading to
pain, loss of function, and a decrease in quality of life
[37]. This also leads to a substantial burden on the
healthcare system [38]. The knee is the most frequently
affected joint, and current efforts to mitigate knee OA
are focused on decreasing pain, increasing function, and
improving quality of life [38]. These current treatment
options have limitations, as symptomatic treatment fails
to address the underlying pathophysiological processes
associated with OA or regenerate injured cartilage [38].
This is one of the several reasons why the field of regenera-
tive medicine and interest in the use of biologics, including
cell-free biologics, has increased so rapidly [27, 34, 37].
This clinical trial will be the first to evaluate the safety
and efficacy of intraarticular cell-free stem cell-derived
extract (CCM) in patients with Kellgren grade II or III
knee OA. We anticipate that the intraarticular injection
of CCM is safe, and participants will show an improve-
ment in their pain, function, quality of life, and overall
satisfaction. We also hypothesize that the cartilage for-
mation over a period of 2 years compared to the baseline
visit will improve. The positive outcomes from this trial
will also lay the foundation for a large randomized,
placebo-controlled, multi-center trial of intraarticular
CCM for symptomatic knee OA.
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